GlassScriptPhysician profile
Brian Thomas Jensen
NPI 1689927964
$4,203.99
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,623 · 2022: $1,668 · 2023: $821 · 2024: $91.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.59 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $682.01 | 2021-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $502.29 | 2021-2023 | |
| Antares Pharma, INC. | $501.84 | 2021-2023 | Tlando, Xyosted, Nocdurna |
| Abbott Laboratories | $314.95 | 2021-2023 | Assurity, Jot Dx, Aveir |
| Novo Nordisk INC | $292.18 | 2022-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $243.64 | 2021-2024 | Mounjaro, Trulicity |
| Astellas Pharma US INC | $201.93 | 2021-2023 | Veozah |
| Glaxosmithkline, LLC. | $180.97 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.67 | 2021-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $151.36 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $143.60 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $63.74 | 2021-2023 | Breztri |
| Amgen INC. | $55.23 | 2022-2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $52.37 | 2022-2023 | |
| Pfizer INC. | $48.36 | 2022-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.